What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Surgery, Adverse effect, Oncology and Clinical trial.
His work on Gastroenterology expands to the thematically related Internal medicine.
His Surgery research incorporates elements of New drug application, Confidence interval, Bortezomib and Lymphoma.
His work deals with themes such as Nausea, Carboplatin, Chemotherapy and Imatinib mesylate, which intersect with Adverse effect.
His Oncology research is multidisciplinary, relying on both Breast cancer, Metastatic breast cancer and Confirmatory trial.
The study incorporates disciplines such as Regimen and Response rate in addition to Clinical trial.
His most cited work include:
- FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma (858 citations)
- Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia (705 citations)
- Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration (523 citations)
What are the main themes of his work throughout his whole career to date?
Richard Pazdur mainly focuses on Internal medicine, Oncology, Surgery, Clinical trial and Pharmacology.
His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology.
His Oncology research includes elements of Cancer, Breast cancer, Metastatic breast cancer and Docetaxel.
Richard Pazdur combines subjects such as Hazard ratio and Confidence interval with his study of Surgery.
His Clinical trial research includes themes of Alternative medicine, Multiple myeloma and Surrogate endpoint.
His work in Pharmacology addresses subjects such as Intensive care medicine, which are connected to disciplines such as Blinding.
He most often published in these fields:
- Internal medicine (68.67%)
- Oncology (42.06%)
- Surgery (33.48%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (68.67%)
- Oncology (42.06%)
- Clinical trial (26.18%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Clinical trial, Surgery and Adverse effect are his primary areas of study.
His study in Internal medicine concentrates on Lung cancer, Chemotherapy, Nausea, Hazard ratio and Cancer.
His Oncology research is multidisciplinary, incorporating elements of Pembrolizumab, Regimen, Randomized controlled trial, Pneumonitis and Nivolumab.
The Clinical trial study combines topics in areas such as Discontinuation, Cohort and Multiple myeloma.
Richard Pazdur studied Surgery and Confidence interval that intersect with Metastatic melanoma.
His Adverse effect research integrates issues from Carcinoma and Drug.
Between 2015 and 2021, his most popular works were:
- First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. (234 citations)
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy (213 citations)
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1 (183 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Chemotherapy
- Internal medicine
Richard Pazdur focuses on Internal medicine, Oncology, Surgery, Adverse effect and Chemotherapy.
His work is connected to Lung cancer, Confirmatory trial, Pneumonitis, Clinical trial and Nausea, as a part of Internal medicine.
His Clinical trial study incorporates themes from Disease progression, Programmed cell death 1 and Immunotherapy.
His Oncology study combines topics from a wide range of disciplines, such as Pembrolizumab, Cancer, Companion diagnostic, Nivolumab and Cohort.
As part of the same scientific family, Richard Pazdur usually focuses on Surgery, concentrating on Confidence interval and intersecting with Carcinoma and Gefitinib.
His biological study spans a wide range of topics, including Alternative medicine, Docetaxel and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
